|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI
|
|
2
|
Baldewijns MM, van Vlodrop IJ, Schouten
LJ, Soetekouw PM, de Bruïne AP and van Engeland M: Genetics and
epigenetics of renal cell cancer. Biochim Biophys Acta.
1785:133–155. 2008.PubMed/NCBI
|
|
3
|
Linehan WM, Schmidt LS, Crooks DR, Wei D,
Srinivasan R, Lang M and Ricketts CJ: The metabolic basis of kidney
cancer. Cancer Discov. 9:1006–1021. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rijnders M, de Wit R, Boormans JL, Lolkema
MPJ and van der Veldt AAM: Systematic review of immune checkpoint
inhibition in urological cancers. Eur Urol. 72:411–423. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lalani AA, McGregor BA, Albiges L,
Choueiri TK, Motzer R, Powles T, Wood C and Bex A: Systemic
treatment of metastatic clear cell renal cell carcinoma in 2018:
Current paradigms, use of immunotherapy, and future directions. Eur
Urol. 75:100–110. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rot A and von Andrian UH: Chemokines in
innate and adaptive host defense: Basic chemokinese grammar for
immune cells. Annu Rev Immunol. 22:891–928. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Griffith JW, Sokol CL and Luster AD:
Chemokines and chemokine receptors: Positioning cells for host
defense and immunity. Annu Rev Immunol. 32:659–702. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagarsheth N, Wicha MS and Zou W:
Chemokines in the cancer microenvironment and their relevance in
cancer immunotherapy. Nat Rev Immunol. 17:559–572. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ozga AJ, Chow MT and Luster AD: Chemokines
and the immune response to cancer. Immunity. 54:859–874. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bule P, Aguiar SI and Aires-Da-Silva Fal
Dias JN: Chemokine-directed tumor microenvironment modulation in
cancer immunotherapy. Int J Mol Sci. 22:98042021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Märkl F, Huynh D, Endres Sal and Kobold S:
Utilizing chemokines in cancer immunotherapy. Trends Cancer.
8:670–682. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Hayer KM, Brady DC and Counter CM:
ELR+CXC chemokines and oncogenic Ras-mediated tumorigenesis.
Carcinogenesis. 30:1841–1847. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Korbecki J, Bosiacki M, Barczak K, Łagocka
R, Brodowska A, Chlubek D and Baranowska-Bosiacka I: Involvement in
tumorigenesis and clinical significance of CXCL1 in reproductive
cancers: breast cancer, cervical cancer, endometrial cancer,
ovarian cancer and prostate cancer. Int J Mol Sci. 24:72622023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yao M, Tabuchi H, Nagashima Y, Baba M,
Nakaigawa N, Ishiguro H, Hamada K, Inayama Y, Kishida T, Hattori K,
et al: Gene expression analysis of renal carcinoma: Adipose
differentiation-related protein as a potential diagnostic and
prognostic biomarker for clear-cell renal carcinoma. J Pathol.
205:377–387. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wozniak MB, Le Calvez-Kelm F,
Abedi-Ardekani B, Byrnes G, Durand G, Carreira C, Michelon J,
Janout V, Holcatova I, Foretova L, et al: Integrative genome-wide
gene expression profiling of clear cell renal cell carcinoma in
Czech Republic and in the United States. PLoS One. 8:e578862013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Richmond A and Thomas HG: Melanoma growth
stimulatory activity: Isolation from human melanoma tumors and
characterization of tissue distribution. J Cell Biochem.
36:185–198. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schumacher C, Clark-Lewis I, Baggiolini M
and Moser B: High- and low-affinity binding of GRO alpha and
neutrophil-activating peptide 2 to interleukin 8 receptors on human
neutrophils. Proc Natl Acad Sci USA. 89:10542–10546. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhuo C, Ruan Q, Zhao X, Shen Y and Lin R:
CXCL1 promotes colon cancer progression through activation of
NF-κB/P300 signaling pathway. Biol Direct. 17:342022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Man X, Yang X, Wei Z, Tan Y, Li W, Jin H
and Wang B: High expression level of CXCL1/GROα is linked to
advanced stage and worse survival in uterine cervical cancer and
facilitates tumor cell malignant processes. BMC Cancer. 22:7122022.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Purdue MP, Rhee J, Moore L, Gao X, Sun X,
Kirk E, Bencko V, Janout V, Mates D, Zaridze D, et al: Differences
in risk factors for molecular subtypes of clear cell renal cell
carcinoma. Int J Cancer. 149:1448–1454. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Do HTT, Lee CH and Cho J: Chemokines and
their receptors: Multifaceted roles in cancer progression and
potential value as cancer prognostic markers. Cancers (Basel).
12:2872020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi YL, Li Y, Man XX, Sui HY, Zhao XL,
Zhang PX, Qu XS, Zhang H, Wang BX, Li J, et al: CXCL3
overexpression promotes the tumorigenic potential of uterine
cervical cancer cells via the MAPK/ERK pathway. J Cell Physiol.
235:4756–4765. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chow MT and Luster AD: Chemokines in
cancer. Cancer Immunol Res. 2:1125–1131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ha H, Debnath B and Neamati N: Role of the
CXCL8-CXCR1/2 axis in cancer and inflammatory diseases.
Theranostics. 7:1543–1588. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang W, Wang H, Sun M, Deng X, Wu X, Ma
Y, Li M, Shuoa SM, You Q and Miao L: CXCL5/CXCR2 axis in tumor
microenvironment as potential diagnostic biomarker and therapeutic
target. Cancer Commun (Lond). 40:69–80. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gui SL, Teng LC, Wang SQ, Liu S, Lin YL,
Zhao XL, Liu L, Sui HY, Yang Y, Liang L, et al: Overexpression of
CXCL3 can enhance the oncogenic potential of prostate cancer. Int
Urol Nephrol. 48:701–709. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xin H, Cao Y, Shao ML, Zhang W, Zhang CB,
Wang JT, Liang LC, Shao WW, Qi YL, Li Y, et al: Chemokine CXCL3
mediates prostate cancer cells proliferation, migration and gene
expression in an autocrine/paracrine fashion. Int Urol Nephrol.
50:861–868. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Largeot A, Pagano G, Gonder S, Moussay E
and Paggetti J: The B-side of cancer immunity: The underrated tune.
Cells. 8:4492019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vilgelm AE and Richmond A: Chemokines
modulate immune surveillance in tumorigenesis, metastasis, and
response to immunotherapy. Front Immunol. 10:3332019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sionov RV, Fridlender ZG and Granot Z: The
multifaceted roles neutrophils play in the tumor microenvironment.
Cancer Microenviron. 8:125–158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yuan M, Zhu H, Xu J, Zheng Y, Cao X and
Liu Q: Tumor-Derived CXCL1 promotes lung cancer growth via
recruitment of tumor-associated neutrophils. J Immunol Res.
2016:65304102016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han KQ, He XQ, Ma MY, Guo XD, Zhang XM,
Chen J, Han H, Zhang WW, Zhu QG and Zhao WZ: Targeted silencing of
CXCL1 by siRNA inhibits tumor growth and apoptosis in
hepatocellular carcinoma. Int J Oncol. 47:2131–2140. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Miyake M, Hori S, Morizawa Y, Tatsumi Y,
Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, et al:
CXCL1-Mediated interaction of cancer cells with tumor-associated
macrophages and cancer-associated fibroblasts promotes tumor
progression in human bladder cancer. Neoplasia. 18:636–646. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Noorolyai S, Shajari N, Baghbani E,
Sadreddini S and Baradaran B: The relation between PI3K/AKT
signalling pathway and cancer. Gene. 698:120–128. 2019. View Article : Google Scholar : PubMed/NCBI
|
